Drug Interactions — MCQs

Q: Warfarin therapy is prolonged by all except:

Rifampicin. The core concept behind this question is the modulation of **Cytochrome P450 (CYP450)** enzymes and the role of intestinal flora in Vitamin K synthesis. **1. Why Rifampicin is the correct answer:** Warfarin is metabolized primarily by the CYP2C9 enzyme. **Rifampicin** is a potent **microsomal enzyme inducer** [2]. By inducing these enzymes, it accelerates the metabolism of Warfarin, leading to decreased plasma levels and a **reduced** anticoagulant effect (shortened prothrombin time). Therefore, it does *not* prolong Warfarin therapy; it antagonizes it. **2. Why the other options are incorrect:** * **Erythromycin:** This is a known **enzyme inhibitor** [1]. It inhibits CYP450 enzymes, slowing down Warfarin metabolism, which increases its plasma concentration and **prolongs** its effect (increasing the risk of bleeding). * **Amoxicillin & Tetracycline:** Broad-spectrum antibiotics prolong Warfarin therapy through a different mechanism [3]. They eliminate **intestinal bacterial flora** that normally synthesize Vitamin K2 [3]. Since Warfarin works by inhibiting Vitamin K epoxide reductase, a reduction in endogenous Vitamin K levels potentiates Warfarin’s anticoagulant action. **Clinical Pearls for NEET-PG:** * **S-Warfarin** is 3-5 times more potent than R-Warfarin and is metabolized by **CYP2C9** [2]. * **Enzyme Inducers (Reduce Warfarin effect):** Phenytoin, Carbamazepine, Phenobarbitone, Rifampicin, Griseofulvin (Mnemonic: **GPRS Cell Phone**). * **Enzyme Inhibitors (Increase Warfarin effect):** Valproate, Ketoconazole, Cimetidine, Erythromycin, Isoniazid (Mnemonic: **Vitamins K, C, E, I**). * **Monitoring:** Warfarin efficacy is monitored using **PT/INR** (Extrinsic pathway) [3].

Q: Which of the following prostaglandin analogues is used in the management of glaucoma?

Latanoprost. **Explanation:** **Latanoprost** is the correct answer because it is a **PGF2α analogue** specifically designed for ophthalmic use. It functions by increasing the **uveoscleral outflow** of aqueous humor, thereby reducing intraocular pressure (IOP). It is considered a first-line treatment for Open-Angle Glaucoma due to its high efficacy and once-daily dosing profile. **Analysis of Incorrect Options:** * **Misoprostol (Option A):** A PGE1 analogue used primarily for the prevention of NSAID-induced gastric ulcers and for medical abortion (in combination with mifepristone). It is not used in ophthalmology. * **Enprostil (Option B) & Rioprostil (Option D):** These are PGE2 and PGE1 analogues, respectively. They were developed as anti-secretory agents to treat peptic ulcer disease by inhibiting gastric acid secretion, but they have no role in glaucoma management. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Prostaglandin analogues (Latanoprost, Bimatoprost, Travoprost) lower IOP by increasing uveoscleral outflow, unlike Beta-blockers which decrease aqueous production. * **Specific Side Effects:** A classic "image-based" or clinical question favorite is the triad of side effects: **Increased pigmentation of the iris** (permanent), **thickening/darkening of eyelashes** (trichomegaly), and **periorbital fat atrophy**. * **Prodrug Status:** Latanoprost is administered as a prodrug to enhance corneal penetration and is hydrolyzed by esterases in the cornea to its active form.

Q: A patient is taking ketoconazole for fungal infection develops a cold for which he is prescribed terfenadine. What is the likely drug interaction between terfenadine and ketoconazole?

Ketoconazole decreases the metabolism of terfenadine.. ### Explanation **1. Why Option A is Correct:** The interaction between ketoconazole and terfenadine is a classic example of **enzyme inhibition**. Ketoconazole is a potent inhibitor of the hepatic microsomal enzyme **CYP3A4**. Terfenadine is a pro-drug that is normally rapidly metabolized by CYP3A4 into its active, non-toxic metabolite (fexofenadine). When ketoconazole is co-administered, it blocks the metabolism of terfenadine, leading to significantly elevated plasma levels of the parent drug. **2. Why the Other Options are Incorrect:** * **Option B:** Terfenadine does not significantly affect the metabolic enzymes responsible for ketoconazole clearance; the interaction is unidirectional. * **Option C:** This is the opposite of the actual effect. Ketoconazole *increases* terfenadine levels by preventing its breakdown. * **Option D:** There is a major, life-threatening interaction between these two drugs, which led to the withdrawal of terfenadine from many markets. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Mechanism of Toxicity:** High levels of terfenadine (and astemizole) block the **delayed rectifier potassium channels (IKr)** in the heart. * **Clinical Outcome:** This leads to **QT interval prolongation**, which can progress to a life-threatening polymorphic ventricular tachycardia known as **Torsades de Pointes**. * **The "Safe" Alternative:** **Fexofenadine** (the active metabolite of terfenadine) is used clinically because it does not block potassium channels and does not cause cardiotoxicity, even in the presence of CYP3A4 inhibitors. * **Other CYP3A4 Inhibitors:** Be wary of similar interactions with Erythromycin, Clarithromycin, and Grapefruit juice.

Q: Which of the following drugs does NOT cause curare-like effects?

Chloramphenicol. ### Explanation The question tests your knowledge of **drug-induced neuromuscular blockade (NMB)**. Certain antibiotics can potentiate the effects of skeletal muscle relaxants or cause "curare-like" effects by interfering with the release of acetylcholine (ACh) or reducing the sensitivity of the motor endplate. **1. Why Chloramphenicol is correct:** **Chloramphenicol** is a protein synthesis inhibitor (50S subunit) that does **not** interfere with neuromuscular transmission. It lacks the chemical structure and mechanism required to inhibit calcium entry or ACh release at the motor nerve terminal. Therefore, it does not cause curare-like paralysis. **2. Why the other options are incorrect:** * **Streptomycin (Aminoglycosides):** This is the most notorious group for this effect. Aminoglycosides (like Streptomycin, Neomycin, Gentamicin) inhibit the pre-junctional release of ACh by competing with **Calcium ions** at the voltage-gated channels. * **Polymyxin (B and Colistin):** These exert a potent "curare-like" effect via a non-competitive blockade at the post-junctional membrane. Their effect is often more difficult to reverse than that of aminoglycosides. * **Tetracycline:** These can cause neuromuscular blockade, likely by chelating calcium ions which are essential for ACh release. **NEET-PG High-Yield Pearls:** * **Reversal:** Aminoglycoside-induced blockade can often be reversed by **Intravenous Calcium Gluconate** (which overcomes the competition) or Neostigmine. * **Contraindication:** These antibiotics should be used with extreme caution in patients with **Myasthenia Gravis** or those receiving neuromuscular blockers (like Succinylcholine or Vecuronium) during surgery. * **Mnemonic:** "Antibiotics that block the NMJ" – **A**minoglycosides, **P**olymyxins, **T**etracyclines, and **L**incosamides (Clindamycin).

Q: A patient receiving allopurinol requires dose reduction of which of the following medications?

6-Mercaptopurine. The correct answer is **6-Mercaptopurine (6-MP)**. This is a classic high-yield drug interaction based on the inhibition of drug metabolism. **Mechanism of Interaction:** 6-Mercaptopurine is an antimetabolite (purine analog) [2] primarily metabolized by the enzyme **Xanthine Oxidase (XO)** into inactive metabolites (6-thiouric acid) [1]. **Allopurinol** is a potent inhibitor of Xanthine Oxidase [1]. When administered concurrently, allopurinol prevents the degradation of 6-MP, leading to toxic plasma levels and severe bone marrow suppression. Therefore, the dose of 6-MP must be reduced to **25–33% (one-fourth to one-third)** of the original dose. **Analysis of Incorrect Options:** * **B. Cyclophosphamide:** This is an alkylating agent metabolized by hepatic CYP450 enzymes, not Xanthine Oxidase. While allopurinol may slightly increase its bone marrow toxicity via different mechanisms, it does not require a standard dose reduction. * **C. 6-Thioguanine:** Unlike 6-MP, 6-Thioguanine is primarily metabolized by **deamination** (guanase) and S-methylation, rather than Xanthine Oxidase [1]. Thus, it can be used at standard doses with allopurinol. * **D. Cimetidine:** This is an H2 blocker and a general CYP450 inhibitor. It does not share a metabolic pathway with allopurinol. **NEET-PG High-Yield Pearls:** 1. **Azathioprine:** Since Azathioprine is a prodrug converted into 6-MP, it also requires a similar dose reduction when given with allopurinol. 2. **Febuxostat:** Like allopurinol, this non-purine XO inhibitor also interacts with 6-MP/Azathioprine. 3. **Tumor Lysis Syndrome:** Allopurinol is often used here to prevent hyperuricemia, making this interaction clinically significant during chemotherapy.

Q: Which of the following drugs has the least affinity for CYP3A4?

Rabeprazole. **Explanation:** The correct answer is **Rabeprazole**. **1. Underlying Medical Concept:** Proton Pump Inhibitors (PPIs) are primarily metabolized in the liver by the cytochrome P450 system, specifically **CYP2C19** and **CYP3A4**. The degree of reliance on these enzymes determines the potential for drug-drug interactions (e.g., with Clopidogrel or Warfarin). **Rabeprazole** is unique because it is predominantly metabolized via a **non-enzymatic pathway** (reduction to rabeprazole thioether) with only minor involvement of the CYP system. Consequently, it has the least affinity for CYP3A4 and CYP2C19 among the PPIs, making its pharmacokinetics less affected by genetic polymorphisms or concurrent drug use. **2. Analysis of Incorrect Options:** * **Omeprazole (A):** This is the prototype PPI and has the **highest affinity** for CYP2C19 and significant affinity for CYP3A4. It is a potent inhibitor of these enzymes, leading to many drug interactions. * **Esomeprazole (C):** As the S-isomer of omeprazole, it is also heavily metabolized by CYP2C19 and CYP3A4, though it shows slightly improved bioavailability. * **Lansoprazole (B):** This drug is extensively metabolized by both CYP2C19 and CYP3A4. While it has a shorter half-life, its dependence on the CYP system is much higher than that of Rabeprazole. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Drug Interactions:** Rabeprazole and **Pantoprazole** are the preferred PPIs for patients on multiple medications (polypharmacy) due to their lower potential for CYP-mediated interactions. * **Clopidogrel Interaction:** Omeprazole inhibits CYP2C19, which prevents the conversion of Clopidogrel (a prodrug) into its active form, increasing the risk of cardiovascular events. * **Genetic Polymorphism:** The efficacy of Omeprazole varies significantly between "Poor Metabolizers" and "Extensive Metabolizers" of CYP2C19; Rabeprazole avoids this variability.

A 50-year-old patient diagnosed with pulmonary tuberculosis is started on standard drug therapy. After 1.5 months, the patient develops fatigue, low-grade fever, muscle aches, bone pains, and body aches. The patient also complains of pleuritic chest pain. Sputum tests are negative for acid-fast bacilli. Further investigations reveal the patient is positive for anti-histone antibodies. Abnormality in which of the following metabolic processes is responsible for the patient's current condition?

Q8Medium

A patient receiving allopurinol requires dose reduction of which of the following medications?

Q9Easy

Which among the following classes of antibiotics are relatively safer to use in patients on Warfarin therapy?

Q10Medium

Which of the following drugs has the least affinity for CYP3A4?

Drug Interactions Indian Medical PG Practice Questions and MCQs

Question 1: Nitrates are contraindicated with which of the following drug classes?

A. Sulphonylureas
B. Immunomodulators
C. Selective Serotonin Reuptake Inhibitors (SSRIs)
D. Phosphodiesterase-5 (PDE-5) inhibitors (Correct Answer)

Explanation: **Explanation:** The contraindication between **Nitrates** and **PDE-5 inhibitors** (e.g., Sildenafil, Tadalafil, Vardenafil) is a classic high-yield pharmacology concept based on their synergistic effect on the **cGMP pathway**. **Mechanism of Interaction:** 1. **Nitrates** act as nitric oxide (NO) donors, which stimulates the enzyme *Guanylate Cyclase*, leading to increased production of **cyclic GMP (cGMP)**. This causes smooth muscle relaxation and vasodilation. 2. **PDE-5 inhibitors** prevent the breakdown of cGMP by inhibiting the enzyme *Phosphodiesterase-5*. 3. When taken together, there is an exaggerated accumulation of cGMP, leading to profound systemic vasodilation. This can result in **severe, life-threatening hypotension**, reflex tachycardia, and potentially fatal myocardial infarction. **Analysis of Incorrect Options:** * **A. Sulphonylureas:** These are oral hypoglycemics (e.g., Glipizide). They do not interact significantly with the NO-cGMP pathway; their primary interaction concern is with drugs that affect blood glucose or protein binding (like sulfonamides). * **B. Immunomodulators:** While these drugs have various side effects, they do not share a common vasodilatory pathway with nitrates. * **C. SSRIs:** These affect serotonin levels in the synaptic cleft. While they have many drug-drug interactions (notably Serotonin Syndrome), they do not cause the acute hemodynamic collapse seen with PDE-5 inhibitors. **Clinical Pearls for NEET-PG:** * **Time Window:** Nitrates should generally be avoided for **24 hours** after Sildenafil/Vardenafil and **48 hours** after Tadalafil (due to its longer half-life). * **Management:** If a patient on this combination develops hypotension, aggressive fluid resuscitation and Trendelenburg positioning are required; nitrates must be stopped immediately. * **Other PDE Inhibitors:** Note that **Milrinone** (PDE-3 inhibitor) is used in heart failure, but the specific contraindication with nitrates is most strictly associated with the PDE-5 class used for erectile dysfunction and pulmonary hypertension.

Question 2: Which drug may inhibit the cytochrome P450 metabolism of warfarin?

A. Cimetidine (Correct Answer)
B. Ethanol
C. Rifampicin
D. Procainamide

Explanation: **Explanation:** The correct answer is **Cimetidine**. This question tests the concept of **Cytochrome P450 (CYP450) enzyme inhibition and induction**, a high-yield topic in NEET-PG pharmacology. **1. Why Cimetidine is Correct:** Cimetidine is a classic **CYP450 enzyme inhibitor**. It binds to the heme iron of the cytochrome P450 system (specifically isoforms like CYP2C9, which metabolizes Warfarin). By inhibiting these enzymes, Cimetidine decreases the metabolism of Warfarin, leading to increased plasma levels of the drug. Clinically, this results in an exaggerated anticoagulant effect, an increased International Normalized Ratio (INR), and a significant risk of bleeding. **2. Analysis of Incorrect Options:** * **Ethanol:** Acute alcohol intake can inhibit enzymes, but **chronic** ethanol consumption is a potent **enzyme inducer**. In the context of standard pharmacology exams, ethanol is generally categorized as an inducer unless "acute intoxication" is specified. * **Rifampicin:** This is one of the most potent **CYP450 enzyme inducers**. It increases the metabolism of Warfarin, thereby *decreasing* its anticoagulant efficacy and lowering the INR. * **Procainamide:** This is a Class 1A antiarrhythmic drug. It is metabolized via **acetylation** (by the NAT2 enzyme), not primarily through the CYP450 system, and does not act as a significant CYP inhibitor. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Enzyme Inhibitors (SICKFACES.COM):** **S**odium Valproate, **I**soniazid, **C**imetidine, **K**etoconazole, **F**luconazole, **A**lcohol (Acute), **C**hloramphenicol, **E**rythromycin, **S**ulfonamides, **C**iprofloxacin, **O**meprazole, **M**etronidazole. * **Warfarin & CYP2C9:** Warfarin has a narrow therapeutic index; always monitor INR when adding any "G-PACMAN" (Inducers) or "SICKFACES" (Inhibitors) drug. * **Cimetidine vs. Ranitidine:** Unlike Cimetidine, newer H2 blockers like Ranitidine or Famotidine have negligible effects on CYP450.

Question 3: Warfarin therapy is prolonged by all except:

A. Rifampicin (Correct Answer)
B. Amoxicillin
C. Erythromycin
D. Tetracycline

Explanation: The core concept behind this question is the modulation of **Cytochrome P450 (CYP450)** enzymes and the role of intestinal flora in Vitamin K synthesis. **1. Why Rifampicin is the correct answer:** Warfarin is metabolized primarily by the CYP2C9 enzyme. **Rifampicin** is a potent **microsomal enzyme inducer** [2]. By inducing these enzymes, it accelerates the metabolism of Warfarin, leading to decreased plasma levels and a **reduced** anticoagulant effect (shortened prothrombin time). Therefore, it does *not* prolong Warfarin therapy; it antagonizes it. **2. Why the other options are incorrect:** * **Erythromycin:** This is a known **enzyme inhibitor** [1]. It inhibits CYP450 enzymes, slowing down Warfarin metabolism, which increases its plasma concentration and **prolongs** its effect (increasing the risk of bleeding). * **Amoxicillin & Tetracycline:** Broad-spectrum antibiotics prolong Warfarin therapy through a different mechanism [3]. They eliminate **intestinal bacterial flora** that normally synthesize Vitamin K2 [3]. Since Warfarin works by inhibiting Vitamin K epoxide reductase, a reduction in endogenous Vitamin K levels potentiates Warfarin’s anticoagulant action. **Clinical Pearls for NEET-PG:** * **S-Warfarin** is 3-5 times more potent than R-Warfarin and is metabolized by **CYP2C9** [2]. * **Enzyme Inducers (Reduce Warfarin effect):** Phenytoin, Carbamazepine, Phenobarbitone, Rifampicin, Griseofulvin (Mnemonic: **GPRS Cell Phone**). * **Enzyme Inhibitors (Increase Warfarin effect):** Valproate, Ketoconazole, Cimetidine, Erythromycin, Isoniazid (Mnemonic: **Vitamins K, C, E, I**). * **Monitoring:** Warfarin efficacy is monitored using **PT/INR** (Extrinsic pathway) [3].

Question 4: Which of the following prostaglandin analogues is used in the management of glaucoma?

A. Misoprostol
B. Latanoprost (Correct Answer)
C. Enprostil
D. Rioprostil

Explanation: **Explanation:** **Latanoprost** is the correct answer because it is a **PGF2α analogue** specifically designed for ophthalmic use. It functions by increasing the **uveoscleral outflow** of aqueous humor, thereby reducing intraocular pressure (IOP). It is considered a first-line treatment for Open-Angle Glaucoma due to its high efficacy and once-daily dosing profile. **Analysis of Incorrect Options:** * **Misoprostol (Option A):** A PGE1 analogue used primarily for the prevention of NSAID-induced gastric ulcers and for medical abortion (in combination with mifepristone). It is not used in ophthalmology. * **Enprostil (Option B) & Rioprostil (Option D):** These are PGE2 and PGE1 analogues, respectively. They were developed as anti-secretory agents to treat peptic ulcer disease by inhibiting gastric acid secretion, but they have no role in glaucoma management. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Prostaglandin analogues (Latanoprost, Bimatoprost, Travoprost) lower IOP by increasing uveoscleral outflow, unlike Beta-blockers which decrease aqueous production. * **Specific Side Effects:** A classic "image-based" or clinical question favorite is the triad of side effects: **Increased pigmentation of the iris** (permanent), **thickening/darkening of eyelashes** (trichomegaly), and **periorbital fat atrophy**. * **Prodrug Status:** Latanoprost is administered as a prodrug to enhance corneal penetration and is hydrolyzed by esterases in the cornea to its active form.

Question 5: A patient is taking ketoconazole for fungal infection develops a cold for which he is prescribed terfenadine. What is the likely drug interaction between terfenadine and ketoconazole?

A. Ketoconazole decreases the metabolism of terfenadine. (Correct Answer)
B. Terfenadine increases the levels of ketoconazole.
C. Ketoconazole decreases the levels of terfenadine.
D. There is no interaction between these drugs.

Explanation: ### Explanation **1. Why Option A is Correct:** The interaction between ketoconazole and terfenadine is a classic example of **enzyme inhibition**. Ketoconazole is a potent inhibitor of the hepatic microsomal enzyme **CYP3A4**. Terfenadine is a pro-drug that is normally rapidly metabolized by CYP3A4 into its active, non-toxic metabolite (fexofenadine). When ketoconazole is co-administered, it blocks the metabolism of terfenadine, leading to significantly elevated plasma levels of the parent drug. **2. Why the Other Options are Incorrect:** * **Option B:** Terfenadine does not significantly affect the metabolic enzymes responsible for ketoconazole clearance; the interaction is unidirectional. * **Option C:** This is the opposite of the actual effect. Ketoconazole *increases* terfenadine levels by preventing its breakdown. * **Option D:** There is a major, life-threatening interaction between these two drugs, which led to the withdrawal of terfenadine from many markets. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Mechanism of Toxicity:** High levels of terfenadine (and astemizole) block the **delayed rectifier potassium channels (IKr)** in the heart. * **Clinical Outcome:** This leads to **QT interval prolongation**, which can progress to a life-threatening polymorphic ventricular tachycardia known as **Torsades de Pointes**. * **The "Safe" Alternative:** **Fexofenadine** (the active metabolite of terfenadine) is used clinically because it does not block potassium channels and does not cause cardiotoxicity, even in the presence of CYP3A4 inhibitors. * **Other CYP3A4 Inhibitors:** Be wary of similar interactions with Erythromycin, Clarithromycin, and Grapefruit juice.

Question 6: Which of the following drugs does NOT cause curare-like effects?

A. Chloramphenicol (Correct Answer)
B. Polymyxin
C. Tetracycline
D. Streptomycin

Explanation: ### Explanation The question tests your knowledge of **drug-induced neuromuscular blockade (NMB)**. Certain antibiotics can potentiate the effects of skeletal muscle relaxants or cause "curare-like" effects by interfering with the release of acetylcholine (ACh) or reducing the sensitivity of the motor endplate. **1. Why Chloramphenicol is correct:** **Chloramphenicol** is a protein synthesis inhibitor (50S subunit) that does **not** interfere with neuromuscular transmission. It lacks the chemical structure and mechanism required to inhibit calcium entry or ACh release at the motor nerve terminal. Therefore, it does not cause curare-like paralysis. **2. Why the other options are incorrect:** * **Streptomycin (Aminoglycosides):** This is the most notorious group for this effect. Aminoglycosides (like Streptomycin, Neomycin, Gentamicin) inhibit the pre-junctional release of ACh by competing with **Calcium ions** at the voltage-gated channels. * **Polymyxin (B and Colistin):** These exert a potent "curare-like" effect via a non-competitive blockade at the post-junctional membrane. Their effect is often more difficult to reverse than that of aminoglycosides. * **Tetracycline:** These can cause neuromuscular blockade, likely by chelating calcium ions which are essential for ACh release. **NEET-PG High-Yield Pearls:** * **Reversal:** Aminoglycoside-induced blockade can often be reversed by **Intravenous Calcium Gluconate** (which overcomes the competition) or Neostigmine. * **Contraindication:** These antibiotics should be used with extreme caution in patients with **Myasthenia Gravis** or those receiving neuromuscular blockers (like Succinylcholine or Vecuronium) during surgery. * **Mnemonic:** "Antibiotics that block the NMJ" – **A**minoglycosides, **P**olymyxins, **T**etracyclines, and **L**incosamides (Clindamycin).

Question 7: A 50-year-old patient diagnosed with pulmonary tuberculosis is started on standard drug therapy. After 1.5 months, the patient develops fatigue, low-grade fever, muscle aches, bone pains, and body aches. The patient also complains of pleuritic chest pain. Sputum tests are negative for acid-fast bacilli. Further investigations reveal the patient is positive for anti-histone antibodies. Abnormality in which of the following metabolic processes is responsible for the patient's current condition?

A. Sulfation
B. Glucuronide conjugation
C. Acetylation (Correct Answer)
D. Hydroxylation

Explanation: ### Explanation The patient is presenting with **Drug-Induced Lupus Erythematosus (DILE)**, a side effect of **Isoniazid (INH)**, which is a core component of the standard anti-tubercular treatment (ATT). **1. Why Acetylation is Correct:** Isoniazid is metabolized in the liver primarily via **N-acetylation** by the enzyme **N-acetyltransferase 2 (NAT2)**. * **The Mechanism:** Individuals are genetically categorized as "Fast Acetylators" or "Slow Acetylators." **Slow acetylators** have a reduced rate of metabolism, leading to higher plasma concentrations of the drug. * **The Pathology:** Elevated levels of INH (or its metabolites) can trigger the formation of **anti-histone antibodies**, leading to a lupus-like syndrome characterized by fever, arthralgia, myalgia, and serositis (pleuritic chest pain). Unlike systemic lupus (SLE), DILE rarely involves the CNS or kidneys and typically resolves upon drug discontinuation. **2. Why Incorrect Options are Wrong:** * **Sulfation & Glucuronide conjugation:** These are Phase II metabolic reactions. While many drugs (like paracetamol or morphine) undergo these processes, they are not the primary metabolic pathway for Isoniazid and are not associated with the development of anti-histone antibodies. * **Hydroxylation:** This is a Phase I (CYP450-mediated) reaction. While some drugs like Phenytoin undergo hydroxylation, it is not the rate-limiting step for INH metabolism nor the cause of DILE. **3. Clinical Pearls for NEET-PG:** * **Classic DILE Drugs (Mnemonic: SHIP):** **S**ulfonamides, **H**ydralazine (highest risk), **I**soniazid, **P**rocainamide (fastest onset). * **Hallmark Lab:** **Anti-histone antibodies** are positive in >95% of DILE cases (Anti-dsDNA is usually negative). * **Slow Acetylators** are also at higher risk for **Peripheral Neuropathy** (due to Vitamin B6 deficiency). * **Fast Acetylators** are at higher risk for **Hepatotoxicity** (due to rapid conversion to acetyl-hydrazine).

Question 8: A patient receiving allopurinol requires dose reduction of which of the following medications?

A. 6-Mercaptopurine (Correct Answer)
B. Cyclophosphamide
C. 6-Thioguanine
D. Cimetidine

Explanation: The correct answer is **6-Mercaptopurine (6-MP)**. This is a classic high-yield drug interaction based on the inhibition of drug metabolism. **Mechanism of Interaction:** 6-Mercaptopurine is an antimetabolite (purine analog) [2] primarily metabolized by the enzyme **Xanthine Oxidase (XO)** into inactive metabolites (6-thiouric acid) [1]. **Allopurinol** is a potent inhibitor of Xanthine Oxidase [1]. When administered concurrently, allopurinol prevents the degradation of 6-MP, leading to toxic plasma levels and severe bone marrow suppression. Therefore, the dose of 6-MP must be reduced to **25–33% (one-fourth to one-third)** of the original dose. **Analysis of Incorrect Options:** * **B. Cyclophosphamide:** This is an alkylating agent metabolized by hepatic CYP450 enzymes, not Xanthine Oxidase. While allopurinol may slightly increase its bone marrow toxicity via different mechanisms, it does not require a standard dose reduction. * **C. 6-Thioguanine:** Unlike 6-MP, 6-Thioguanine is primarily metabolized by **deamination** (guanase) and S-methylation, rather than Xanthine Oxidase [1]. Thus, it can be used at standard doses with allopurinol. * **D. Cimetidine:** This is an H2 blocker and a general CYP450 inhibitor. It does not share a metabolic pathway with allopurinol. **NEET-PG High-Yield Pearls:** 1. **Azathioprine:** Since Azathioprine is a prodrug converted into 6-MP, it also requires a similar dose reduction when given with allopurinol. 2. **Febuxostat:** Like allopurinol, this non-purine XO inhibitor also interacts with 6-MP/Azathioprine. 3. **Tumor Lysis Syndrome:** Allopurinol is often used here to prevent hyperuricemia, making this interaction clinically significant during chemotherapy.

Question 9: Which among the following classes of antibiotics are relatively safer to use in patients on Warfarin therapy?

A. Cephalosporins
B. Imidazoles
C. Penicillins (Correct Answer)
D. Macrolides

Explanation: **Explanation:** The interaction between antibiotics and Warfarin is a high-yield topic in pharmacology. Warfarin is an oral anticoagulant that acts as a Vitamin K antagonist. Its therapeutic index is narrow, and its metabolism is highly susceptible to drug interactions. **Why Penicillins are the correct answer:** Penicillins (e.g., Amoxicillin, Ampicillin) are considered relatively safer because they do not significantly inhibit the hepatic **Cytochrome P450 (CYP450)** enzymes responsible for Warfarin metabolism (specifically CYP2C9). While most broad-spectrum antibiotics can theoretically increase the International Normalized Ratio (INR) by eradicating gut flora that produce Vitamin K, the clinical impact of Penicillins on Warfarin levels is generally minimal compared to other classes. **Why the other options are incorrect:** * **Macrolides (e.g., Erythromycin, Clarithromycin):** These are potent **CYP3A4 and CYP2C9 inhibitors**. They decrease the metabolism of Warfarin, leading to toxic levels and a high risk of bleeding. * **Imidazoles (e.g., Metronidazole):** Metronidazole is a strong inhibitor of **CYP2C9**, the primary enzyme that metabolizes the more potent S-isomer of Warfarin. This is a classic, dangerous drug interaction. * **Cephalosporins:** Certain cephalosporins (especially those with a **Methylthiotetrazole/MTT side chain** like Cefotetan or Cefoperazone) inhibit Vitamin K epoxide reductase, exerting a prothrombin-depressing effect similar to Warfarin, which significantly increases bleeding risk. **NEET-PG High-Yield Pearls:** 1. **The "Big Inhibitors":** Remember the mnemonic **"SICKFACES.COM"** for CYP inhibitors; Metronidazole and Macrolides are major culprits. 2. **Rifampicin Exception:** Rifampicin is a potent **CYP inducer**, which *decreases* Warfarin levels, potentially leading to subtherapeutic INR and thrombosis. 3. **Safe Alternatives:** Besides Penicillins, first-generation Cephalosporins (like Cephalexin) are generally considered lower risk than other classes.

Question 10: Which of the following drugs has the least affinity for CYP3A4?

A. Omeprazole
B. Lansoprazole
C. Esomeprazole
D. Rabeprazole (Correct Answer)

Explanation: **Explanation:** The correct answer is **Rabeprazole**. **1. Underlying Medical Concept:** Proton Pump Inhibitors (PPIs) are primarily metabolized in the liver by the cytochrome P450 system, specifically **CYP2C19** and **CYP3A4**. The degree of reliance on these enzymes determines the potential for drug-drug interactions (e.g., with Clopidogrel or Warfarin). **Rabeprazole** is unique because it is predominantly metabolized via a **non-enzymatic pathway** (reduction to rabeprazole thioether) with only minor involvement of the CYP system. Consequently, it has the least affinity for CYP3A4 and CYP2C19 among the PPIs, making its pharmacokinetics less affected by genetic polymorphisms or concurrent drug use. **2. Analysis of Incorrect Options:** * **Omeprazole (A):** This is the prototype PPI and has the **highest affinity** for CYP2C19 and significant affinity for CYP3A4. It is a potent inhibitor of these enzymes, leading to many drug interactions. * **Esomeprazole (C):** As the S-isomer of omeprazole, it is also heavily metabolized by CYP2C19 and CYP3A4, though it shows slightly improved bioavailability. * **Lansoprazole (B):** This drug is extensively metabolized by both CYP2C19 and CYP3A4. While it has a shorter half-life, its dependence on the CYP system is much higher than that of Rabeprazole. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Drug Interactions:** Rabeprazole and **Pantoprazole** are the preferred PPIs for patients on multiple medications (polypharmacy) due to their lower potential for CYP-mediated interactions. * **Clopidogrel Interaction:** Omeprazole inhibits CYP2C19, which prevents the conversion of Clopidogrel (a prodrug) into its active form, increasing the risk of cardiovascular events. * **Genetic Polymorphism:** The efficacy of Omeprazole varies significantly between "Poor Metabolizers" and "Extensive Metabolizers" of CYP2C19; Rabeprazole avoids this variability.

Practice by Chapter

Mechanisms of Drug Interactions

Practice Questions

Pharmacokinetic Interactions

Practice Questions

Pharmacodynamic Interactions

Practice Questions

Drug-Food Interactions

Practice Questions

Drug-Disease Interactions

Practice Questions

Clinically Significant Drug Interactions

Practice Questions

Computer Systems for Detecting Drug Interactions

Practice Questions

Management of Drug Interactions

Practice Questions

Drug Interactions in Special Populations

Practice Questions

Role of P-glycoprotein in Drug Interactions

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free